Bleeding with menopausal hormone therapy: Physiological or pathological?

Menopause International

Volumn 13, Issue 4, 2007, Pages 188-190

  Hickey, Martha ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

BLEEDING; ENDOMETRIUM; ESTROGEN; HORMONE REPLACEMENT THERAPY; PROGESTOGEN

Indexed keywords

ESTROGEN; GESTAGEN; MATRIX METALLOPROTEINASE; THROMBOSPONDIN 1; TIBOLONE; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULOTROPIN; ESTRADIOL;

BLEEDING; CANCER RISK; CLINICAL ASSESSMENT; CONFERENCE PAPER; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; EPITHELIUM; HEMOSTASIS; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; HYSTEROSCOPY; LOW DRUG DOSE; MENOPAUSE; MENSTRUATION; PATHOLOGY; PATIENT SAFETY; PHYSIOLOGICAL PROCESS; TRANSVAGINAL ECHOGRAPHY; BLOOD VESSEL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; REVIEW; UTERUS BLEEDING; VASCULAR ENDOTHELIUM; WOMEN'S HEALTH;

BLOOD VESSELS; ENDOMETRIUM; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; PROGESTINS; UTERINE HEMORRHAGE; WOMEN'S HEALTH;

EID: 41949109306     PISSN: 17540453     EISSN: None     Source Type: Journal    
DOI: 10.1258/175404507783004005     Document Type: Review

References (32)

1. MacLennan AH, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews 2002;288:CD002978.
2. Christodoulakos GE, Botsis DS, Lambrinoudaki IV, et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas 2006; 53:413–23.
3. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686–92.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33.
5. Elliott J, Connor ME, Lashen H. The value of outpatient hysteroscopy in diagnosing endometrial pathology in postmenopausal women with and without hormone replacement therapy. Acta Obstet Gynecol Scand 2003;82:1112–19.
6. Wells M, Sturdee DW, Barlow DH, et al. Effect on endometrium of long term treatment with continuous combined estrogen/progestogen replacement therapy: follow up study. BMJ 2002;325: 239–42.
7. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911–18.
8. Wildemeersch D, Janssens D, Pylyser K, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007;57:210–13.
9. Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 1989;59:445–7.
10. Bjarnason NH. Endometrial cancer and hormone-replacement therapy. Lancet 2005;366:200–1.
11. Pukkala E, Tulenheimo-Silfvast A, Leminen A. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994–1997. Cancer Causes Control 2001;12:111–15.
12. Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas 2007;57:81–4.
13. Scottish Intercollegiate Guidelines Network. See http://www. sign.ac.uk (last accessed September 2007).
14. Akkad AA, Habiba MA, Ismail N, Abrams K, al-Azzawi F. Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities. Obstet Gynecol 1995;86:330–4.
15. Perrone G, DeAngelis C, Critelli C, et al. Hysteroscopic findings in postmenopausal abnormal uterine bleeding: a comparison between HRT users and non-users. Maturitas 2002;43:251–5.
16. Goldstein SR, Zeltser I, Horan CK, et al. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol 1997;177:102–8.
17. Van den Bosch T, Van Schoubroeck D, Ameye L, et al. Ultrasound assessment of endometrial thickness and endometrial polyps in women on hormonal replacement therapy. Am J Obstet Gynecol 2003;188:1249–53.
18. Thomas AM, Hickey M, Fraser IS. Disturbances of endometrial bleeding with hormone replacement therapy. Hum Reprod 2000; 15 (Suppl 3):7–17.
19. Smith SK. Steroids and endometrial breakthrough bleeding: future directions for research. Hum Reprod 2000;15 (Suppl 3):197–202.
20. Archer DF. Endometrial bleeding during hormone therapy: the effect of progestogens. Maturitas 2007;57:71–6.
21. Hickey M, Dwarte D, Fraser IS. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding. Hum Reprod 2000;15:1509–14.
22. Hickey M, Fraser IS. A functional model for progestogen-induced breakthrough bleeding. Hum Reprod 2000;15:1–6.
23. Hickey M, Pillai G, Higham JM, et al. Changes in endometrial blood vessels in the endometrium of women with hormone replacement therapy-related irregular bleeding. Hum Reprod 2003;18:1100–6.
24. Hickey M, Doherty DA, Fraser IS, et al. Why does menopausal hormone therapy (HT) lead to irregular uterine bleeding? Changes to endometrial blood vessels. Hum Reprod 2007 (in press).
25. Runic R, Schatz F, Wan L, et al. Effects of norplant on endometrial tissue factor expression and blood vessel structure. J Clin Endocrinol Metab 2000;85:3853–9.
26. Jones RL, Morison NB, Hannan NJ, et al. Chemokine expression is dysregulated in the endometrium of women using progestinonly contraceptives and correlates to elevated recruitment of distinct leukocyte populations. Hum Reprod 2005;20:2724–35.
27. Peloggia A, Petta CA, Bahamondes L, et al. Endometrial chemokines, uterine natural killer cells and mast cells in long-term users of the levonorgestrel-releasing intrauterine system. Hum Reprod 2006;21:1129–34.
28. Hickey M, Crewe J, Goodridge JP, et al. Menopausal hormone therapy and irregular endometrial bleeding: a potential role for uterine natural killer cells? J Clin Endocrinol Metab 2005;90: 5528–35.
29. Salamonsen LA, Zhang J, Brasted M. Leukocyte networks and human endometrial remodelling. J Reprod Immunol 2002;57:95– 108.
30. Salamonsen LA, Woolley DE. Menstruation: induction by matrix metalloproteinases and inflammatory cells. J Reprod Immunol 1999;44:1–27.
31. Hickey M, Higham J, Sullivan M, Miles L, Fraser IS. Endometrial bleeding in hormone replacement therapy users: preliminary findings regarding the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of MMPs. Fertil Steril 2001;75:288–96.
32. Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904–11.